Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

FG-3019 safe and well tolerated in phase II study in IPF

Sep. 10, 2012

Phase II zabofloxacin results presented at ICAAC

Sep. 10, 2012

ILLUMINATE, SHINE and ENLIGHTEN study results presented

Sep. 7, 2012

Almirall presents phase III study results for aclidinium bromide in patients with COPD

Sep. 7, 2012

Results from three clinical studies reported for AZD-5069

Sep. 7, 2012

Targacept presents results for its nicotinic acetylcholine receptor agonists

Sep. 7, 2012

Study evaluates dose-response of umeclidinium in COPD

Sep. 6, 2012

New lysophospholipid S1P1 receptor agonists presented at ACS meeting

Sep. 6, 2012

Phase II results demonstrate efficacy of QMF-149 in patients with persistent asthma

Sep. 6, 2012

Mepolizumab reduces exacerbation rates in asthma patients

Sep. 6, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...